CTSO Stock Forecast: CytoSorbents Corp. Price Predictions for 2026-2027
The median 12-month analyst price target for CytoSorbents Corp. is $33. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 70 of 100 as at 21 Nov 2026 — in the upper half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores CytoSorbents Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (93): Reported profit is backed by cash, and the company is not expanding recklessly.
Issuance (21): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
CTSO stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on CTSO, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 21 Oct 2026 | WBB Securities | Initiates | Speculative Buy | $9.50 |
| 26 Mar 2026 | D. Boral Capital | Maintains | Buy | $10 |
| 12 Jan 2026 | D. Boral Capital | Maintains | Buy | — |
| 16 Dec 2025 | D. Boral Capital | Maintains | Buy | — |
| 14 Nov 2025 | D. Boral Capital | Maintains | Buy | — |
| 14 Nov 2025 | HC Wainwright & Co. | Maintains | Neutral | — |
| 16 Sept 2025 | D. Boral Capital | Maintains | Buy | — |
| 20 Aug 2025 | D. Boral Capital | Maintains | Buy | — |
| 8 Aug 2025 | D. Boral Capital | Maintains | Buy | — |
| 21 July 2025 | D. Boral Capital | Maintains | Buy | — |
| 25 June 2025 | D. Boral Capital | Maintains | Buy | — |
| 15 May 2025 | D. Boral Capital | Maintains | Buy | — |
| 15 May 2025 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 2 May 2025 | D. Boral Capital | Maintains | Buy | — |
| 3 Apr 2025 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 1 Apr 2025 | D. Boral Capital | Maintains | Buy | — |
| 25 Feb 2025 | D. Boral Capital | Maintains | Buy | — |
| 13 Jan 2025 | D. Boral Capital | Maintains | Buy | — |
| 3 Jan 2025 | D. Boral Capital | Maintains | Buy | — |
| 12 Nov 2024 | D. Boral Capital | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for CTSO.
This page is one stock. Monday covers all of them.
CTSO appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
CTSO analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 0.4×
- Price / book
- —
- EV / EBITDA
- —
Cheaper than 82% of US stocks
- Revenue growth (YoY)
- 2.6%
- Earnings growth (YoY)
- —
- Gross margin
- 73.2%
- Operating margin
- −27.7%
- Net margin
- −45.1%
Higher than 34% of US stocks
Higher than 85% of US stocks
Higher than 21% of US stocks
Higher than 11% of US stocks
- Return on equity
- —
- Return on assets
- −15.6%
- Dividend yield
- —
Higher than 22% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
CytoSorbents Corp. has a market value of $16.2M and an enterprise value of $41.5M.
Revenue in the twelve months to 30 June 2026: $37.2M. The latest quarter grew 0.2% year on year.
Net income over the same four quarters: −$18.2M, a −48.9% net margin.
Diluted earnings per share, trailing twelve months: −$5.80.
Free cash flow in the twelve months to 30 June 2026: −$9.6M.
CytoSorbents Corp. employs 129 people — $288K of revenue per employee.
Data provided by Twelve Data
CTSO and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at CTSO’s peer groups, ranked by the model: healthcare stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own CytoSorbents Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about CTSO
What is the CTSO stock price forecast for 2026-2027?
The median 12-month analyst price target for CytoSorbents Corp. is $33, with estimates ranging from $15 to $50. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is CTSO stock a buy right now?
Of the 1 analyst covering CytoSorbents Corp., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks CytoSorbents Corp. 70 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank CTSO?
As at 21 Nov 2026, CytoSorbents Corp. ranks 70 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (93 of 100).
Will CTSO stock go up?
No one can know that. What the data says: the median 12-month target from 1 analyst is $33, and Ticker Nerd's factor model ranks CytoSorbents Corp. 70 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the CTSO stock forecast for 2030?
No analyst covering CytoSorbents Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CTSO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $15 to $50 over the next 12 months.
What does CytoSorbents Corp. do?
CytoSorbents Corporation is a medical device company focused on blood purification technologies for critical care and cardiac surgery. CytoSorbents Corporation develops and commercializes products that use hemoadsorption to remove harmful substances from blood, including inflammatory mediators, bilirubin, myoglobin, and certain antithrombotic drugs.
About CytoSorbents Corp.
CytoSorbents Corporation is a medical device company focused on blood purification technologies for critical care and cardiac surgery. CytoSorbents Corporation develops and commercializes products that use hemoadsorption to remove harmful substances from blood, including inflammatory mediators, bilirubin, myoglobin, and certain antithrombotic drugs. Its portfolio includes CytoSorb for intensive care and surgical applications, DrugSorb-ATR for removing blood thinners, and additional blood purification and filtration technologies for specialized clinical and veterinary uses. The company serves hospitals and clinicians in the United States, Europe, and other international markets, with an emphasis on treating life-threatening conditions such as sepsis, severe inflammation, and complications associated with surgery and organ failure. Headquartered in Princeton, New Jersey, CytoSorbents Corporation plays a niche role in the medical technology market through its proprietary polymer-based adsorption platform.
CEO Dr. Phillip P. Chan M.D., Ph.D. · 129 employees · United States · https://www.cytosorbents.com